A Repair “Kit” for the Infarcted Heart  by Mignone, John L. & Murry, Charles E.
Cell Stem Cell
Previewsindividuals with DM1, indicating that the
toxic RNA is expressed in the relevant
cells (Wheeler et al., 2007).
In childhood/juvenile-onset DM1, the
major neurologic phenotypes are often
related to behavioral changes, such as
anxiety, attention deficit hyperactivity
disorder, autistic behavior, and obses-
sive-compulsive behavior (Meola and
Sansone, 2007). In CDM1, mental retar-
dation is frequently observed in conjunc-
tion with the aforementioned behavioral
phenotypes. In adult DM1, similar behav-
ioral changes have been observed in
many patients, including anxiety, ob-
sessive-compulsive behavior, attention
deficit disorder, and apathy. In this
regard, it is of particular interest that in
recent studies using knockout mice defi-
cient for various Slitrk family members,
a variety of behavioral phenotypes
(anxiety, obsessive-compulsive behavior)
and disorganized/reduced innervations350 Cell Stem Cell 8, April 8, 2011 ª2011 Elshave been noted (reviewed in Proenca
et al., 2011). While it may be premature
and speculative, the results from these
knockout mice and the decreased levels
of SLITRK2 and SLITRK4 in brains from
DM1 patients support the hypothesis
that the effects of the DM1 mutation on
SLITRK members may contribute to the
behavioral phenotypes observed in DM1
patients. At the least, this study provides
a new target for investigating the
pathology of DM1 in the brain in the
many existing mouse models of RNA
toxicity and highlights the potential of
studies using hESCs to help unravel the
pathogenesis of DM1 and other rare
disorders.REFERENCES
Aruga, J., and Mikoshiba, K. (2003). Mol. Cell.
Neurosci. 24, 117–129.evier Inc.Lee, J.E., Lee, J.Y., Wilusz, J., Tian, B., andWilusz,
C.J. (2010). PLoS ONE 5, e11201.
Llamusi, B., and Artero, R. (2008). Curr. Genomics
9, 509–516.
Marteyn, A., Maury, Y., Gauthier, M.M., Lecuyer,
C., Vernet, R., Denis, J.A., Pietu, G., Peschanski,
M., and Martinat, C. (2011). Cell Stem Cell 8, this
issue, 452–462.
Meola, G., and Sansone, V. (2007). Muscle Nerve
36, 294–306.
Panaite, P.A., Gantelet, E., Kraftsik, R., Gourdon,
G., Kuntzer, T., and Barakat-Walter, I. (2008). J.
Neuropathol. Exp. Neurol. 67, 763–772.
Proenca, C.C., Gao, K.P., Shmelkov, S.V., Rafii, S.,
and Lee, F.S. (2011). Trends Neurosci. 34,
143–153.
Stranock, S.D., and Davis, J.N. (1978). Neuropa-
thol. Appl. Neurobiol. 4, 407–418.
Wheeler, T.M., Krym, M.C., and Thornton, C.A.
(2007). Neuromuscul. Disord. 17, 242–247.
Yadava, R.S., Frenzel-McCardell, C.D., Yu, Q.,
Srinivasan, V., Tucker, A.L., Puymirat, J., Thornton,
C.A., Prall, O.W., Harvey, R.P., and Mahadevan,
M.S. (2008). Nat. Genet. 40, 61–68.A Repair ‘‘Kit’’ for the Infarcted HeartJohn L. Mignone1 and Charles E. Murry1,2,3,*
1Department of Medicine/Cardiology
2Department of Pathology
3Department of Bioengineering and Center for Cardiovascular Biology
Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA
*Correspondence: murry@u.washington.edu
DOI 10.1016/j.stem.2011.03.005
Transplanted, c-kit expressing marrow-derived progenitors can enhance the function of an infarcted heart,
but the mechanism remains unclear. In this issue of Cell Stem Cell, Loffredo et al. (2011) provide evidence
that hematopoietic precursors do not differentiate into new cardiomyocytes but, rather, stimulate production
of new cardiomyocytes from endogenous progenitors.The stem cell biology field is no stranger
to paradigm shifts, in particular when
reevaluating presumed terminally differ-
entiated tissue. As has been the case in
several adult tissues, much interest over
the past decade has been directed to the
possibility that regenerative progenitor
cells exist in the mature heart. The
hearts of amphibians and teleost fish
retain the ability to regenerate throughout
life, and recent work in zebrafish has
demonstrated this repair process occurs
principally through division of pre-existingcardiomyocytes (Kikuchi et al., 2010).
Interestingly, the mouse heart retains the
ability to regenerate for a few days after
birth, again through cardiomyocyte divi-
sion, but this replication competence is
lost within the first week of postnatal life
(Porrello et al., 2011). While mature
mammalian hearts clearly lack a robust
regenerative response, mounting evi-
dence points to some capacity for cardio-
myocyte renewal. In 2007, Richard Lee’s
group performed a lineage tracing experi-
ment to elegantly demonstrate that,indeed, the young adult mouse heart can
generate new cardiomyocytes post
myocardial infarction (Hsieh et al., 2007).
Using this system, they fluorescently
labeled 80% of the pre-existing cardio-
myocytes and then demonstrated that,
8 weeks post-myocardial infarction, the
percentage of fluorescently labeled
mature cardiomyocytes had fallen to
roughly 65%, with 15% new cardiomyo-
cytes likely arising from a progenitor pop-
ulation. Since this study, Frisen’s group
demonstrated that the adult human heart
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Figure 1. Genetic Lineage Tracing System for the Detection of Cardiomyocytes
Regeneration
The constitutively active b-actin promoter drives expression of a loxP flanked b-galactosidase gene (b-gal,
shown in blue). In the presence of cre-recombinase, the b-gal gene is floxed out, now allowing the b-actin
promoter to drive EGFP expression (shown in green). In this double transgenic system, the Cre recombi-
nase is under the transcriptional control of theMyh6 promoter, confining expression tomature cardiomyo-
cytes. The cre-recombinase is also fused to the mutant estrogen receptor ‘‘Mer,’’ which constrains the
protein to the cytoplasm until tamoxifen is present. By administering a daily dose of tamoxifen to
6-week-old mice for 2 weeks, 80% of mature cardiomyocytes were permanently labelled green. Following
myocardial infarction, this percentage falls to 60% in the infarct border zone as new cardiomyocytes arise.
If, at the time of myocardial infarction, bonemarrow derived c-kit+ cells are administered to the heart, even
more new cardiomyocytes are made and the percentage of green cardiomyocytes in the infarction border
zone falls to only 50% of cardiomyocytes. No increase in new cardiomyocytes is seen over sham control if
mesenchymal stem cells (MSCs) or resident cardiac c-kit+ cells are added.
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Previewshas the potential to regenerate cardio-
myocytes at a low rate throughout adult-
hood (0.4%–1%/year; Bergmann et al.,
2009). Clearly, the therapeutic implica-
tions of a non-cardiomyocyte regenera-
tive population make these cells a prime
target for further characterization.
In the current issue of Cell Stem Cell,
Loffredo et al. (2011) reuse this pulse-
chase system to assess how c-kit+ bone
marrow progenitors improve function of
the infarcted mouse heart. This question
addresses a controversial area of
research, with initial studies suggesting
that hematopoietic c-kit+ progenitors
transdifferentiate into cardiomyocytes
(Orlic et al., 2001), and subsequent studies
demonstrating that these cells mature into
inflammatory cells in the heart without
becoming cardiomyocytes (Murry et al.,2004; Balsam et al., 2004). Loffredo et al.
demonstrate that marrow-derived c-kit+
cells canhave a significant impact onheart
regeneration, not as direct progenitors but
as regulators of an endogenous cardiac
stem or progenitor cell. Their genetic
pulse-chase system uses the Z/EG
reporter mouse crossed with a mouse ex-
pressing the tamoxifen-inducible form of
Cre recombinase only in cardiomyocytes.
The strategy, therefore, is to label pre-
existing cardiomyocytes with EGFP and
then assess dilution of this EGFP+ pool
after injury, which would indicate repopu-
lation from an EGFP-negative progenitor
pool (Figure 1). Toward that end, 6-week-
old mice were given daily tamoxifen injec-
tions for 2 weeks, achieving EGFP labeling
of approximately 80%of allmature cardio-
myocytes, while in 20%, recombinationCell Stem Cdid not occur and the cells continued to
express b-gal. The labeled hearts were
then infarcted, and 6 3 105 lineage/
c-kit+ bone marrow cells or marrow-
derived mesenchymal stem cells (MSCs)
from wild-type animals were administered
to the medial and lateral infarct borders.
Animals were allowed to recover for
8weeksand thenassessedby immunohis-
tochemistry for the frequency of EGFP-
and b-gal-expressing cardiomyocytes.
Similar to their prior study, control
infarcted mice had 20% reduction in
the number of EGFP-labeled cardiomyo-
cytes, consistent with the generation of
new cardiomyocytes from progenitor
cells. Hearts that received MSCs were
no different from controls, indicating
MSCs neither influence endogenous
progenitors nor become cardiomyocytes
themselves. The mice that received the
c-kit+ cells, however, had a 30% reduc-
tion in the number of EGFP+ cardiomyo-
cytes, suggesting an augmentation of
endogenous cardiac progenitor activity.
This effect was found only in the region
of c-kit injection and not in remote areas
(which had 7% reduction in EGFP+
cardiomyocytes). These new cardiomyo-
cytes all expressed b-gal and, therefore,
were not due to differentiation of the
transplanted wild-type c-kit+ cells into
mature cardiomyocytes. Further evalua-
tion demonstrated that administration of
c-kit+ cells also increased the number of
cells expressing early cardiomyocyte
transcription factors Gata4 or Nkx2.5 by
approximately 3-fold and that these cells
were actively synthesizing DNA. This pop-
ulation may represent an expanding
subset of nascent cardiomyocytes or their
progenitors, although at present the origin
of these cells remains unclear (Figure 1).
While the authors conclude that their
results support themodel that an endoge-
nous cardiac stem cell exists and that its
activity can be potentiated by c-kit+
hematopoetic stem cells, Loffredo et al.
took pains to assay for other possible
explanations, including transdifferentia-
tion or cell fusion. They designed genetic
systems to test for transdifferentiation,
but surprisingly, they found that the
transplanted cells did not persist in the
hearts 8weeks later. Indeed, they showed
that Y chromosome+ graft cells could
be detected in the peri-infarct zones up
to 7 days post-transplant, but none re-
mained at 4 weeks. This result effectivelyell 8, April 8, 2011 ª2011 Elsevier Inc. 351
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Previewsrules out transdifferentiation or fusion as
underlying mechanisms responsible for
the new cardiomyocytes seen at 8 weeks.
One remaining possibility is that the 20%
of cardiomyocytes in which the Cre
system failed to induce recombination is
somehow different from the other 80%,
e.g., in this population’s ability to re-enter
the cell cycle. The initial paper describing
this system found no differences in DNA
synthesis rates at selected times postin-
farction (Hsieh et al., 2007), but this
general caveat is worth keeping in mind.
The chemokine stromal-derived factor-
1 (SDF-1, a.k.a. CXCL12) is upregulated
in the infarcted heart and mediates
homing of marrow-derived c-kit+ cells
from the circulation. To assess whether
recruitment of circulating c-kit+ stem cells
could mimic effects of exogenous c-kit+
cells, a protease-resistant version of
SDF-1 was directly administered to the
infarcted heart. In previous studies, this
factor are increased recruitment of
CXCR4+/c-kit+ progenitor cells to the site
of administration and increasedmicrovas-
cular density (Segers et al., 2007). While
SDF-1 administration did recapitulate
increased vascularization, no enhance-
ment in derivation of cardiomyocytes
from progenitors was seen.
A good experiment often opens up
more questions than it answers, and that352 Cell Stem Cell 8, April 8, 2011 ª2011 Elsis the case with this study from Loffredo
et al. What are the cardiomyocyte progen-
itor cells? The genetic system provides
strong evidence for their function, but it
cannot identify them. These candidate
stem cells are clearly not the transplanted
c-kit+ cells from bone marrow, and
the authors’ transplantation studies do
not favor either resident cardiac c-kit+
cells (because transplanted resident
cardiac c-kit+ cells did not survive to
form new cardiomyocytes) or marrow-
derived MSCs. Perhaps the activity
resides within perivascular Sca1+ cell,
the Hoechst dye-effluxing side popula-
tion, or something beyond the list of usual
suspects. Another important question
is how do marrow-derived c-kit+ cells
exert their effects, and is this mechanism
a normal component of the inflammatory
response to infarction that is revealed by
cell transplantation? If we can identify
these paracrine signals, perhaps we can
control their responses without resorting
to cell therapy. Despite these open ques-
tions, the study by Loffredo et al. helps
elucidate the role of bonemarrow-derived
c-kit+ cells to expand the endogenous
cardiomyocyte population, and it demon-
strates, excitingly, that this endogenous
population can be manipulated and
enriched. Thus, we are brought a step
closer to one of the most exciting newevier Inc.therapeutics in the field of cardiovascular
medicine.
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Growing evidence shows that stem cells are modulated by systemic factors that are integrated with local
signals in response to physiological status. Two recentCell (Chell and Brand, 2010) andNature (Sousa-Nunes
et al., 2011) papers reveal that Drosophila neural stem cell proliferation is controlled by a diet-dependent
insulin/TOR signaling relay between tissues.Despite intensive research on stem cells,
a largely unanswered question is how
the behavior of these key cell populationsis influenced by the physiological state
of the organism. Studies using adult
Drosophila stem cells have shed somelight on this question and reveal para-
digms that may be applicable to mamma-
lian systems. Several groups, including
